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ORIGINAL ARTICLE

Population Pharmacokinetic/Pharmacodynamic
Modeling of Depot Testosterone Cypionate in Healthy
Male Subjects
Youwei Bi1, Paul J. Perry1,2, Michael Ellerby2 and Daryl J. Murry3*

A randomized, double-blind clinical trial was conducted to investigate long-term abuse effects of testosterone cypionate (TC).
Thirty-one healthy men were randomized into a dose group of 100, 250, or 500 mg/wk and received 14 weekly injections of TC.
A pharmacokinetic/pharmacodynamic (PK/PD) model was developed to characterize testosterone concentrations and link
exposure to change in luteinizing hormone and spermatogenesis following long-term TC administration. A linear onecompartment model best described the concentration-time profile of total testosterone. The population mean estimates for
testosterone were 2.6 kL/day for clearance and 14.4 kL for volume of distribution. Weight, albumin, and their changes from
baseline were identified as significant covariates for testosterone. The estimated potency of total testosterone (tT) with
respect to suppression of luteinizing hormone (LH) synthesis was 9.33 ng/mL. Simulation based on the indirect response
model suggests the suppression of endogenous testosterone secretion, LH synthesis, and spermatogenesis was more severe
and of greater duration in the 250 mg and the 500 mg dose groups.
CPT Pharmacometrics Syst. Pharmacol. (2018) 7, 259–268; doi:10.1002/psp4.12287; published online 1 March 2018.
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE
TOPIC?
þ Long-term excessive dosing of anabolic steroids can
lead to serious health risks. One of the most significant
physiologic changes induced by the use of testosterone
esters is a dose-dependent impairment of normal testicular androgen secretion and spermatogenesis.
WHAT QUESTION DID THIS STUDY ADDRESS?
þ This study characterizes and quantifies changes in
testosterone and LH concentration, and spermatogenesis following long-term TC administration.
WHAT DOES THIS STUDY ADD TO OUR
KNOWLEDGE?
þ The study developed a PK/PD model based on a randomized three-arm (100 mg, 250 mg, and 500 mg/week)
Endogenous testosterone is responsible for stimulation and
development of male sex organs and for maintenance of
secondary male characteristics.1 An abnormally low level of
testosterone is referred to as hypoandrogenism, in men it
may result in decreased sex hormone production and deficiency in gamete production and regulation. Depottestosterone (testosterone cypionate (TC)) is an oil-soluble
ester of the hormone testosterone and is indicated for
hormone replacement therapy in men who have symptoms
of deficiency or absence of endogenous testosterone.2
It can be used to treat both congenital and acquired
hypoandrogenism.3
Aside from the therapeutic indications, the illegal use of
TC and other anabolic steroids by athletes to gain an unfair
advantage in athletic competitions have been reported for

clinical trial, which quantified the relationship between
testosterone exposure after exogenous administration
and suppression of LH and spermatogenesis. Model
results showed that the suppression of endogenous testosterone secretion, LH synthesis, and spermatogenesis
was more severe and of greater duration in the 250 mg
and the 500 mg dose groups.
HOW MIGHT THIS CHANGE DRUG DISCOVERY,
DEVELOPMENT, AND/OR THERAPEUTICS
þ This PK/PD model provides a framework to quantify
and predict the change in LH and spermatogenesis
after exogenous testosterone administration. The average concentration of tT in the past 18 weeks was found
to have the strongest association with suppression of
spermatogenesis.

over 50 years.4–6 Numerous studies have shown that longterm use or excessive dosing of anabolic steroids can lead
to serious health risks. One physiologic change is a dosedependent impairment of normal testicular androgen secretion and spermatogenesis.7–9 This effect is believed to
result from the suppression of circulating luteinizing hormone (LH) and follicle stimulating hormone through a feedback loop system of the hypothalamic-pituitary-gonadal
(HPG) axis.9,10 Most studies evaluating anabolic steroid
use are observational and retrospective with studied doses
substantially lower than the dose commonly used by illicit
steroid users.11–14
A randomized, double-blind, placebo-controlled study was
conducted by MacIndoe et al.11 to investigate the effects of
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Table 1 Baseline demographic characteristics, protein levels, and laboratory test values of 31 healthy volunteers.
Median (range)
Characteristic

100 mg (N 5 10)

250 mg (N 5 10)

500 mg (N 5 11)

Baseline tT, ng/mL

6.44 (4.04–9.5)

5.93 (4.2–10.6)

5.78 (2.31–9.48)

Baseline fT, ng/dL

2.41 (1.58–4.17)

2.38 (0.28–3.55)

2.44 (1.08–3.09)

Age, years

26.5 (22–32)

25.5 (22–39)

Weight, kg

82.2 (61.7–115)

88.8 (61.7–105)

30 (21–39)
84.7 (60.7–115)

Blood urea nitrogen, mg/dL

14.5 (10–17)

15 (9–18)

Serum creatinine, mg/dL

1.05 (0.8–1.5)

1.1 (1–1.2)

Creatinine clearance, mL/min

124 (89.6–179)

123 (90.4–153)

125 (84.3–166)

Albumin, g/dL

4.55 (4.4–6.9)

4.55 (4.3–5.1)

4.6 (1.6–5)

Globulin, g/dL

2.75 (2–3.1)

Thyroxine-binding globulin, ug/mL

19.5 (10–31)

18.5 (11–26)

21 (14–26)
22 (13–47)

Sex hormone-binding globulin, nmol/L

2.9 (2.4–3.5)

15 (8–19)
1 (0.9–1.2)

3 (2.8–3.2)

26 (17–46)

24.5 (11–48)

Alkaline phosphatase, IU/L

63.5 (52–89)

52 (41–97)

67 (50–98)

Lactate dehydrogenase, IU/L

157 (141–194)

158 (121–196)

143 (111–184)

AST, IU/L

23 (17–32)

20.5 (14–53)

ALT, IU/L

22 (16–52)

27.5 (12–47)

18 (12–34)
19 (10–40)

GGT, IU/L

22 (10–54)

20 (10–54)

18 (10–58)
7.6 (7.1–8)

Total bilirubin, mg/dL

7.25 (6.9–8.1)

7.5 (6.8–8.4)

Direct bilirubin, mg/dL

0.2 (0.2–0.4)

0.25 (0.1–0.4)

0.3 (0.1–0.5)

Triglyceride, mg/dL

110 (40–335)

122 (43–532)

123 (58–538)

Cholesterol, mg/dL

198 (162–241)

199 (140–238)

184 (139–224)

HDL, mg/dL

39 (27–70)

39 (21–54)

33 (22–47)

LDL, mg/dL

125 (65–186)

116 (79–162)

136 (79–181)

ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyl transferase; HDL, high-density lipoprotein; LDL, low-density lipoprotein; fT, free testosterone; tT, free testosterone.

weekly TC injections upon the HPG axis. Our main objective
of developing a pharmacokinetic/pharmacodynamic (PK/PD)
model based on these data is to characterize and quantify
the effect of long-term administration of supratherapeutic
doses of TC on suppression of LH synthesis and spermatogenesis. This information may help us better understand the
effect of the illegal use of anabolic steroids on the impairment of testicular androgen secretion.
METHODS
Study design
The study design of the trial has been published elsewhere.11 In summary, this is a randomized, double-blind
clinical trial in which 31 healthy male subjects were randomized into the 100 mg/wk (n 5 10), 250 mg/wk (n 5 10),
and 500 mg/wk (n 5 11) dose groups. The high dosing regimens of 250 mg/week and 500 mg/week resemble doses
illegally used by athletes. The study included two consecutive weekly injections of TC placebo, followed by 14 consecutive weekly TC injections. This dosing regimen was
chosen to mimic the common cycling duration observed in
the community.6 After the last weekly injection of active
agent, the subjects received 12 consecutive weeks of TC
placebo injections.
All blood samples were collected between 7 AM and 9 AM.
After the last injection of TC, serum was obtained for total
testosterone (tT) and free testosterone (fT) determinations
at biweekly intervals of 7 days. The tT and fT values measured in samples drawn immediately postdose, after
CPT: Pharmacometrics & Systems Pharmacology

8 hours, and then daily for 26 consecutive days after the
last active TC injection were used to determine their elimination. Biweekly luteinizing hormone releasing hormone
(LHRH) stimulation tests were performed 7 days after the
last injection of either placebo or testosterone to assess
pituitary gonadotropin secretion. Venous blood samples for
LH and follicle stimulating hormone were obtained before
and 30, 60, and 120 minutes after the intravenous infusion
of 100 mcg LHRH. Semen samples were obtained by masturbation at baseline (week 0), and weeks 2, 16, 21, 28,
and, in some subjects, at week 40, and assessed for total
and motile sperm concentrations. Subjects were asked to
be sexually abstinent for 24 hours before sample collection.
Model building
Nonlinear mixed effects modeling was performed using
NONMEM version 7.2. The PK/PD data analysis was performed sequentially. The PK model for tT was first fitted to
the data, and the PD model for suppression of LH synthesis,
and spermatogenesis was then sequentially fitted conditional
on fixed individual PK parameters. Detailed description of
model development, model evaluation, and covariate selection can be found in the Supplementary Material. A variety
of compartmental models were evaluated with the modeling
attempts to fit the interplay between testosterone and LH
guided by the known physiology in the HPG axis. Potential
covariates (all covariates listed in Table 1) were selected
based on the physiological plausibility and prior knowledge
from published literature. The potential covariates were
tested in a stepwise manner on clearance (CL), volume (V),
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and absorption rate Ka, as implemented in PsN.15 Effect of
covariates was illustrated using simulations that accounted
for parameter precision of fixed effects.

Table 2 Population pharmacokinetic parameter estimates and bootstrap
results for total testosterone in 31 healthy volunteers.

Median

RSE (%)

95% CI

CL/F, kL/day

2.6

2.6

4.53

(2.42–2.8)

V/F, kL

14.4

14.4

12.1

(11.9–17.6)

Ka, day21

1.22

1.22

44.9

(0.785–2.67)

Parameter

RESULTS
Population pharmacokinetics of testosterone cypionate
Baseline demographic characteristics and laboratory tests
for 31 subjects are summarized in Table 1. Overall, 729 tT
and 379 LH serum samples were available. Among these
observations, 299 tT samples were obtained within 26 days
from the last dose. These samples were used to determine
the main PK parameters.
The data were best fit using a one-compartment model
with linear elimination and first-order absorption. Following
the cessation of TC administration, tT concentrations were
lower than pretreatment concentrations initially and then
slowly returned back to baseline. Initially, the inhibition of
endogenous testosterone was modeled with constant
reduction of its secretion rate in prespecified intervals from
week 4 to week 19 to derive post hoc PK parameters as
inputs for PD model development. The model was then
updated with an indirect maximum effect (Emax) model to
describe the positive regulation of LH on testosterone
secretion. The individual post hoc LH prediction from the
PD model was used in this indirect model because of different sampling time of testosterone and LH.
The differential equation describing the testosterone PKs
is shown below:
d ðABS Þ
52ka  ABS
d ðt Þ
d ðTe Þ
CL
5bi 1ka  ABS2
 Te
d ðt Þ
V
bi 5bbase 1Emax 

LH k
LH k 1LH50 k

where ka is the first-order absorption rate, and CL and V
are clearance and central volume of distribution. The tT
secretion rate bi is equal to bbase plus upregulation through
LH concentration. The initial condition for Te was estimated
as fixed parameter with random effect during model development. The Emax represents the maximum effect of LH on
endogenous testosterone secretion, and LH, LH50, and k
represent LH concentration, the LH concentration when its
upregulation on endogenous testosterone secretion reaches
half of the maximum effect, and hill coefficient.
The final PK parameters for total testosterone are shown
in Table 2. The CL/F and V/F for tT were estimated to be
2.6 (kL/day) and 14.4 kL in healthy men with median
covariate values. The median post hoc half-life was calculated to be 4.05 days for tT. The Emax and LH50 describing
the positive regulation of LH concentration on the testosterone secretion rate were estimated to be 12.5 mg/day and
12.9 IU/L. The estimates of CL and V were insensitive to
the inclusion of LH upregulation on the endogenous secretion rate; the difference in mean post hoc CL and V was
found to be within 20% when compared to the model

Bootstrapa

Final model
Estimate

bbase , mg/day

6.24

6.25

23.3

(3.53–8.09)

LambdaðkÞ

1.18

1.43

55.9

(0.43–2.74)

Emax , mg/day

12.5

12.3

25.2

(7.75–18)

LH50 , IU/L

12.9

12.7

63.1

(0.892–23.7)

A_0, TC

6.24

6.21

5.82

(5.63–6.85)

hBalbumin2V

21.55

21.84

58.7

(23.56 to 20.842)

hCalbumin2V

20.27

20.27

25.4

(20.369 to 20.108)

hBWT2V

1.71

1.77

36.7

(0.776–2.98)

hBWT2CL

0.785

0.793

17.4

(0.595–1.03)

hCWT2CL

0.016

0.016

45.2

(0.00382–0.0254)
(0.00261–0.839)

r2 additive

0.261

0.191

105

r2 proportional

0.057

0.057

18.7

(0.039–0.073)

9.66% (25.2)

8.60%

57.3

(2.98%–12.29%)

IIV_CLb
IIV_V

37% (14.6)

35.9%

52.8

(18.3%–51.7%)

IIV_Ka

53.9% (42.5)

52.4%

89.7

(0.54%–87.5%)

IIV_Emax

45.3% (16.3)

43.1%

71.6

(14.5%–66.3%)

IIV_k

75.9% (25.3)

72.9%

47.4

(40.0%–99.6%)

IIV_A_0, TC

13.6% (49.6)

13.3%

77.1

(0.14%–21.3%)

CI, confidence interval; CL, clearance; Emax, maximum effect; IIV, interindividual variability; RSE%, percentage of relative standard error; TC, testosterone cypionate; V, volume.
a
Median, RSE, and 95% CIs were calculated based on 500 nonparametric
bootstrap results.
b
Shrinkage of IIV parameters was reported along with parameter estimates.

without LH upregulation. A combined additive and proportional model was applied to model the residual error.
Significant covariates for tT included baseline weight,
baseline albumin, and change in weight and albumin from
baseline. Power models for baseline weight and albumin,
linear models for change in albumin, and exponential models for change in weight resulted in the lowest objective
function values (OFVs). The Forest plot of covariate effects
(Figure 1) illustrates that albumin, change in albumin from
baseline, and change in weight from baseline are not clinically important for the testosterone PK parameters, as the
majority of 95% confidence interval (CI) of these covariate
effects fall within the interval of 0.8 to 1.25. On the other
hand, a heavier subject (95th percentile, 110 kg) is estimated to have a 1.23 (95% CI 5 1.16–1.32) and 1.58 (95%
CI 5 1.17–2.3) fold higher CL/F and V/F compared to a typical subject (median 5 85 kg), respectively, suggesting
weight had a modest effect on TC PKs. However, considering the natural variation in testosterone concentrations,
weight-based dosing is not likely to be needed for an i.m.
injection of TC. Of 496 observations for covariates weight,
albumin, and globulin, missing values were replaced by the
previous measurements in 30 (6.05%), 9 (1.81%), and 10
(2.02%) time points, respectively. Basic goodness of fit
(GOF) plots for tT are shown in Supplementary Figure S1.
Prediction-corrected visual predictive checks (VPCs) stratified on dose groups are shown separately for intensive and
www.psp-journal.com
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Figure 1 Effect of baseline and time-varying covariates on pharmacokinetic parameters (clearance (CL) and volume (V)) and pharmacodynamic parameters for suppression of luteinizing hormone (half-maximal inhibitory concentration (IC50), Kin) and spermatogenesis
(Cavg50 ). Error bars indicate 95% confidence interval based on a nonparametric bootstrap.

extensive sampling periods in Figure 2. Overall, the GOF
plots and the prediction-corrected VPCs indicated that the
model adequately describes the central tendency and the
variability of the PK profile of testosterone.
Suppression of luteinizing hormone and
spermatogenesis
The PD end point was chosen to be the LH concentration
at 30 minutes after the stimulation test (LH30). An indirect
effect model best described the LH30 observations:
dðLH30 Þ
5Kin ð12INHÞ2Kout  LH30
dðtÞ
INH describes the inhibitory effect of testosterone on LH
synthesis using sigmoid Emax model with effect compartment: INH 5 Cke /(Cke 1TCk50 ). The Ce is the hypothetical
effect compartment concentration accounting for the lag
between the increase in testosterone and the loss of LH.
The TC50 is the tT concentration when LH synthesis is
inhibited by half. The Emax is fixed to 1 as LH synthesis is
fully inhibited during the study. The initial condition for LH30
is equal to Kin divided by Kout. The final PD model estimates and covariate-parameter relationships are shown in
Table 3. The TC50 and k were estimated to be 9.33 ng/mL
and 18.3, respectively. Baseline weight and thyroxin were
found to be significant covariates for IC50 and Kin. Based
on the Forest plot of covariate effects shown in Figure 1,
the 95% CI of effects of weight on TC50 and thyroxin on Kin
were almost fully outside of the specified interval 0.8 to
CPT: Pharmacometrics & Systems Pharmacology

1.25, indicating potential clinical significance. The TC50 of a
heavier subject (95th percentile, 110 kg) is estimated to be
0.74 (95% CI 5 0.58–0.91) fold of that of a typical subject
with median weight (85 kg). Simulated LH profiles in subjects with different body weights and thyroxin values are
shown in Supplementary Figure S2. Based on simulation,
LH suppression in volunteers with larger body weight is
estimated to last longer. No difference in simulated LH suppression was identified among volunteers with different thyroxin values. Sensitivity analyses were also conducted to fit
the same indirect response model to end points LH60 and
LH120. All models had similar parameter estimation and
comparable performance.
Semenogram data were available in 29 subjects, with two
subjects not providing sample due to vasectomies. A total
of 159 sperm samples were obtained over the 40 weeks of
study. A total of 11 subjects missed 15 of 174 (8.6%)
planned visits for collection of sperm samples; 7 subjects
(24.1%) missed the sample collection at the end of the
study, which might bias the estimate of suppression level of
spermatogenesis at that time point. Because there is a very
high correlation between sperm count and sperm motility
(adjusted R2 5 0.87), the sperm count was used as the
main PD end point. An indirect effect model best described
the sperm counts over time, the differential equation of
which is the same as the indirect model used to fit LH suppression. The average tT concentration across different
time periods (from Cavg since the beginning to Cavg in the
past week) preceding each observation were selected to
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Figure 2 Prediction-corrected visual predictive check for total testosterone obtained from 1,000 simulations stratified on dose and sampling period. Black solid points are observed concentrations. Red solid and dashed lines represent 2.5th, 50th, and 97.5th percentiles
of observed data. The shaded areas indicate simulation-based 95% confidence intervals around the median (orange) and the 2.5th
and 97.5th percentiles (blue) from 1,000 simulations with the final model. Note: All subjects received 14 weekly injections of testosterone cypionate (TC) from week 2 to week 15. Intensive pharmacokinetic sampling was collected immediately postdose, at 8 hours, and
then daily for 26 consecutive days after the last active TC injection (week 15).

represent testosterone exposure and its associations with
suppression of spermatogenesis. The inhibition of testosterone dosing on spermatogenesis over time was best described
by an indirect sigmoid Emax model without effect compartk
ment: INH512Emax Cavg k = Cavg k 1Cavg50
. Cavg in the
past 18 weeks (Cavg_18 weeks) was found to best describe
the effect of exogenous testosterone administration on suppression of spermatogenesis (with lowest OFV). The
Cavg_18 weeks for semen data measured at a time <18
weeks (baseline and between 2 and 16 weeks) is the average
concentration from beginning to the time of measurement.

Logistic transformation was applied on Emax in order to conexp ðPHI Þ
strain its value between 0 and 1: Emax 5 11exp
ðPHI Þ : An additive
error model was applied to PHI, and exponential error models
were applied to Kin, k; and Cavg50 : A sensitivity analysis
using sperm motility as the PD end point with the same indirect response model was also conducted and had similar
parameter estimation and comparable performance. Final PD
model estimates for suppression of sperm counts and sperm
motility are shown in Table 3 and Supplementary Table S1.
Cavg50 was estimated to be 8.68 ng/mL. Baseline weight was
found to be a significant covariate for Cavg50. The Cavg50 of
www.psp-journal.com
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Table 3 Population pharmacodynamic estimates and bootstrap results of
suppression of LH synthesis and sperm count following long-term dosing of
testosterone cypionate in 31 healthy volunteers.

Parameter

Final model
estimate

Bootstrapa
Median

RSE (%)

95% CI

LH
Kin, IU/day

1.7

1.7

14.4

(1.36–2.16)

Kout, L/day

0.11

0.11

10.8

(0.093–0.133)

Test50 ; ng/mL

9.33

Lambda; k

18.3

ke0 ; mL/day

0.0321

r2 additive

0.397

hBwt2IC50

21.14

9.35
18.7

5.62

(8.55–10.1)

21.6

(13.6–27.3)

0.0318

11.2

(0.0261–0.0377)

0.395

10.8

(0.331–0.463)

38.9

(21.88 to 20.494)

21.13

1.19

1.22

27.1

(0.916–1.96)

IIV_Kinb

39.2% (14)

37.6%

51.4

(21.5%–52.4%)

IIV_IC50

27.7% (53.5)

27.1%

32.2

(19.0%–33.3%)

IIV_k

42.2% (7.2)

38.0%

103

(0.42%–71.6%)

IIV_ke0

46.6% (0.5)

45.2%

43.7

(31.1%–64.3%)

hBthyroxin2Kin

Sperm count
Kin,/day

6.17

Kout,/day

0.0696

Cavg50 ; ng/mL

8.68

Lambda; k

11.3

Phi ð/Þ
hBwt2Cavg50
r2 additive

4.65
21.27
0.429

6.40

58.5

(4.92–9.02)

0.0714

59.3

(0.0616–0.0966)

8.74

10.5

(7.3–10.3)

31.5

(6.89–19.7)

11.7
4.58

19.2

(3.67–6.47)

21.25

37.5

(22.06 to 20.536)

0.421

19

(0.311–0.56)

IIV_Kinb

46.8% (14.2)

45.8%

35.2

(31.6%–59.3%)

IIV_Phi ð/Þ

234% (35.9)

214%

73.6

(110%–377%)

IIV_Cavg50

23.2% (18.6)

22.4%

57.4

(9.33%–31.53%)

IIV_k

100% (28.9)

98.3%

60.6

(63.8%–159.7%)

CI, confidence interval; LH, luteinizing hormone; RSE%, percentage of relative standard error.
a
Median, RSE, and 95% CIs were calculated based on 500 nonparametric
bootstrap results.
b
Shrinkage of IIV parameters was reported along with parameter estimates.

a heavier subject (95th percentile, 110 kg) was estimated to
be 0.72 (95% CI 5 0.55–0.91) fold of that of a typical subject
with median weight (85 kg).
Basic GOF plots were plotted against observations of LH
and sperm counts and motility in Supplementary Figure S3.
The visual predictive checks (VPC) for LH and sperm counts
are shown in Figure 3. Overall, diagnostic plots show that
indirect response models were able to describe the suppression of LH synthesis and spermatogenesis after long-term
dosing of TC.
The magnitude and variability of suppression of LH and
sperm counts based on post hoc parameters at each dose
level were summarized and shown in Figure 4. Both the
observed data (black dots) and suppression level generated
from post hoc parameters (colored line and areas) suggest
the suppression of LH was more severe in the 250 mg and
the 500 mg groups, whereas the suppression is variable in
the 100 mg group. The median suppression level for the
100 mg group was >90% and has a wide CI during 14
weeks of active TC dosing. On the other hand, the lower
bound of 90% CI of suppression level was higher than 98%
from week 7 to week 16 in the 250 mg group and from
week 12 to week 17 in the 500 mg group. The recovery of
CPT: Pharmacometrics & Systems Pharmacology

suppression of LH synthesis was also found to be slower in
the 500 mg group compared to the 250 mg and the
100 mg groups. The median suppression level dropped to
below 10% in week 10 after the last testosterone administration in the 500 mg group, compared after week 5 in the
100 mg group and week 6 in the 250 mg group.
Similarly, the suppression of sperm counts was much
more severe in the high dose groups (Figure 4). At the end
of 14 weeks of TC dosing, the sperm count was found to
be completely suppressed in both the 250 mg and the
500 mg groups. The median suppression level at week 15
in the 250 mg and the 500 mg groups were simulated to be
98.2% and 94.9%, respectively. The recovery of sperm
secretion (Kin) also seems to be slower in the higher dose
group, with the median suppression level estimated to be
66.9% for 500 mg group, 48.4% for 250 mg group, and
26.6% for the 100 mg group at week 28, respectively. At
the end of the study period (week 40) the sperm secretion
(Kin) almost returned to normal in the 100 mg and the
250 mg groups, but the sperm counts in some subjects are
still lower than baseline values (suppression level 5 24.0;
95% CI 5 0–67%). As there were 7 subjects (24.1%) who
missed the semen collection at the end of the study, a sensitivity analysis including 22 subjects with complete data
only was conducted, and parameter estimates were very
similar (data not shown).
DISCUSSION
Following the depot administration of TC, the PKs of tT
were satisfactorily described by the one-compartmental
model with first-order absorption. The limited number of
samples in the absorption phase (1–2 samples per subject)
prevents using a more plausible absorption model for the
high lipophilicity of testosterone in an oil base and administered i.m., such as a mixed zero-order and first-order model
with lag time.16 This could lead to flip-flop PKs and can
cause difficulties in estimation and interpretation of PK
parameters.17 The half-life of testosterone undecanoate
(TU) following oral administration is around 150 minutes,18
which is very different from the half-life estimate of 21–34
days following the i.m. injection of TU reported by Behre
et al.19 The large difference in half-lives of TU between oral
and i.m. formulation suggests that flip-flop PKs are occurring
with testosterone esters, which is also reported in the published literature20 and for the i.m. injection of nandrolone.21
The i.m. injection of TC is also likely to have flip-flop kinetics,
in such a scenario, diffusion and release from an oily depot
site is the rate-limiting step to systemic availability.
Endogenous testosterone secretion was described by the
combination of basal testosterone secretion and positive
regulation by LH. The LH stimulates Leydig cell production
of testosterone. The interplay between LH and testosterone
after treatment with gonadotropin-releasing hormone (GnRH)
agonists and antagonists has also been described previously.22 The positive regulation of LH was completely suppressed between week 13 and week 17 for the 100 mg
group and between week 7 and week 19 for the 250 mg
and the 500 mg dose groups, which is consistent with the
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Figure 3 Visual predictive checks for luteinizing hormone (left) and sperm counts (right) obtained from 1,000 simulations. Black solid
points are observed concentrations. Red solid and dashed lines represent 2.5th, 50th, and 97.5th percentiles of observed data. The
shaded areas indicate simulation-based 95% confidence intervals around the median (orange) and the 2.5th and 97.5th percentiles
(blue) from 1,000 simulations with the final model.

clinical observation that it took shorter time to observe the
loss of basal and LHRH-stimulated LH in the 250 mg and
the 500 mg groups. The mean post hoc endogenous testosterone secretion rate at baseline in PK models for tT
models was 12.5 mg/day. It is suggested that men produce
between 4 and 11.8 mg of testosterone per day,23 which is
slightly lower than our model estimate. However, there is
wide variability in normal testosterone concentrations with
ranges reported between 300 and 1,000 ng/dl,24 our model
estimates of endogenous testosterone secretion rate are
consistent with reported values and close to reported physiological values. The endogenous testosterone secretion
rate over time is presented in Figure 4. Inhibition of endogenous secretion lasted longer and was more severe in the
250 mg and the 500 mg groups. The upregulation of LH on
endogenous testosterone secretion was completely lost during week 9 to week 19 in both the 250 mg and the 500 mg
groups. The endogenous testosterone secretion rate
returned to baseline at approximately week 23 in all three
dose groups. The parameter estimates (LH50 5 12.9 IU/L;
Emax 5 12.5) of downregulation of endogenous testosterone
through inhibition of LH was slightly different from those
reported by Tornøe et al.22 (LH50 5 5.18 IU/L; Emax 5 77.5),
but they are not directly comparable because we use different differential equation to fit the interplay between LH and
testosterone secretion.
Inclusion of time-varying covariates besides resulted in
lower interindividual variability on the main PK tT parameters.

However, changes in weight and albumin concentrations
were likely not clinically significant. Analysis of covariate
effects suggests baseline weight is the only potential covariate of clinical importance for the PKs of TC.
It is difficult to calculate the PK parameters of TC using
traditional noncompartmental methods, especially when the
endogenous testosterone secretion rate is suppressed during the course of TC administration and the testosterone
secretion rate is regulated by the LH-testosterone feedback
loop system in HPG axis. Our estimated post hoc median
tT half-life was 4.05 days, which is shorter than the mean
reported elimination half-life of 6.9 days determined using a
noncompartmental analysis.11 Such inconsistency is
believed to result from failure to consider endogenous testosterone production. When we assume endogenous testosterone secretion is 0 in the PPK analysis, the median
estimated half-life increases to 6.87 days.
There are no population PK data available for the longterm supratherapeutic administration of testosterone ester.
The developed model-based PPK approach allowed us to
estimate endogenous testosterone production rate during
and after TC administration.
After characterizing the PKs of long-term TC dosing in
healthy male subjects, the PD model was sequentially
developed. An indirect response model was used to
describe the change of LH30 during and after TC dosing.
The LH concentration after a stimulation test was chosen
as the PD marker in part because the response of LH to
www.psp-journal.com
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Figure 4 Summary of level of suppression of endogenous testosterone secretion (top), luteinizing hormone synthesis (LH; middle), and
sperm counts (bottom) over time during and after testosterone cypionate dosing based on post hoc parameters from 31 subjects. Colored solid lines represent the median suppression level. Horizontal dashed line represents basal endogenous testosterone secretion
independent of LH upregulation. Shaded areas indicate 95% confidence interval of the suppression level. Blue: 100 mg, Red: 250 mg,
and Green: 500 mg. Black solid points represent the observed percentage change of variable of interest (LH30 or sperm counts) from
baseline. The size of black points represents the frequency of observations.

the stimulation test was different across all three TC dose
groups. The lag between loss of basal and stimulated LH
levels has been previously observed.25 The ability of exogenous testosterone administration to suppress LH release
was incorporated into the PD model. A sigmoid Emax model
was applied to link testosterone concentrations with its
inhibitory effect on LH synthesis. The addition of an effect
compartment accounted for the lag between loss of LH and
the increase in testosterone concentration.
We developed a PD model to describe the inhibition of
spermatogenesis during TC dosing and the subsequent
recovery. The effect of average tT concentration during different dosing intervals preceding each sperm observation
was tested on spermatogenesis in the indirect sigmoid
Emax model. The average testosterone concentration in the
past 18 weeks preceding each observation was found to
result in the lowest OFV. The effect of tT Cavg across
CPT: Pharmacometrics & Systems Pharmacology

different time periods on suppression of sperm counts was
also tested. Bias in VPC and simulation results was identified using exposure metrics with shorter observation periods than 14 weeks. The requirement of long-time PK
measurement preceding each semen data aligns well with
the clinical observation that suppression level of spermatogenesis at 13 weeks after the last active TC administration
was still high in both the 250 mg and 500 mg dose groups,
although it may limit the practical applicability of the model.
To the best of our knowledge, this is the first time the relationship between testosterone exposure after exogenous
administration and suppression of spermatogenesis has
been quantified. The Cavg of testosterone in the past 18
weeks was found to have the strongest association with
suppression of spermatogenesis and also provided information regarding the duration of effect of TC administration on
spermatogenesis.
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Most studies evaluating abuse effects of androgen steroids are observational studies and study designs are often
not randomized, double-blind, or placebo-controlled. Subjects are usually exposed to a dose much lower than what
is commonly used by illicit steroid users and administered
for only a short period. The untoward effects of anabolic
steroids on a healthy body, therefore, may be underestimated in the literature. To best of our knowledge, this is the
first time a mechanistic population PK/PD model has been
developed to quantify the relationship between testosterone
exposure after exogenous administration and subsequent
suppression of LH and spermatogenesis during and after
long-term supratherapeutic administration of testosterone
ester in healthy subjects. Tornøe et al.22 developed a PK/
PD model of HPG axis describing the changes in LH and
testosterone concentrations after treatment with GnRH agonist triptorelin and GnRH receptor blocker degarelix. Pechstein et al. adequately described the PK/PD relationship
between plasma levels of Cetrorelix and testosterone suppression following a single i.v. and s.c. dosing. However,
only one single i.v. or s.c. administration was given to
healthy subjects in both studies and neither captured the
change in spermatogenesis. The proposed PK/PD model
in our analysis allows for the quantification and comparison of the suppression of LH synthesis and spermatogenesis at various time points during and after administration
of exogenous testosterone esters. We were also able
to extrapolate the recovery of LH secretion and spermatogenesis in future time points based on post hoc
parameters.
One limitation of the current study is PPK model was
developed based on the data from 31 healthy subjects, the
precision of estimated covariate effects (Figure 1) was
expected to be relatively low due to the small sample size.
Re-estimation of the PK parameters may be necessary if
the current PPK model is going to be applied to the patient
population. A series of physiological changes in renal function, body composition, or protein concentrations is likely to
affect the binding affinity of testosterone as well as the PK
profile of exogenous testosterone administration in the
elderly patients.26,27 Certain patient populations may also
have lower levels of endogenous testosterone secretion,
and altered bbase compared with our model estimates. The
small sample size (N 5 31) may limit the precise estimation
of suppression level of LH and spermatogenesis. The LH
suppression for the 250 mg and 500 mg doses during TC
administration were consistent and severe, whereas it was
variable for the 100 mg dose. The variability of LH recovery
after TC administration was large in all three groups. Similarly, for spermatogenesis, suppression at week 15 and
week 21 were precisely estimated but recovery was estimated with wide CIs. The study design did not follow subjects long enough to allow observation of complete
recovery from inhibition of spermatogenesis, which may
have contributed to the high uncertainty in the estimates of
Kin and Kout.
In summary, we developed a PK/PD model to characterize the PK profile of tT following long-term weekly
injection of TC, and linked testosterone exposure to the
PD effects, including suppression of LH synthesis and

spermatogenesis and their recovery during TC dosing in
healthy men. Our model supports the finding that the
suppression of endogenous testosterone secretion, LH
synthesis, and spermatogenesis is more severe and of
greater duration in subjects receiving higher TC doses.
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